Last reviewed · How we verify

Glycyrrhetinyl Acetate — Competitive Intelligence Brief

Glycyrrhetinyl Acetate (acetoxolone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: acetoxolone. Area: Gastroenterology.

unknown acetoxolone Corticosteroid 11-beta-dehydrogenase isozyme 2 Gastroenterology Live · refreshed every 30 min

Target snapshot

Glycyrrhetinyl Acetate (acetoxolone). Acetoxolone works by inhibiting the enzyme that converts cortisol into its inactive form, allowing more cortisol to be available to reduce inflammation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Glycyrrhetinyl Acetate TARGET acetoxolone unknown acetoxolone Corticosteroid 11-beta-dehydrogenase isozyme 2
Glycyron glycyrrhizic acid marketed glycyrrhizic acid High mobility group protein B1, Corticosteroid 11-beta-dehydrogenase isozyme 2, Corticosteroid 11-beta-dehydrogenase isozyme 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (acetoxolone class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glycyrrhetinyl Acetate — Competitive Intelligence Brief. https://druglandscape.com/ci/acetoxolone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing